Medicines

Find Medicines

Search 21,000+ medicines by brand, generic, indication, or drug class

Medicine Indications Drug Classes
    Showing all medicines (21591 total)

    Cefazid

    Ceftazidime Pentahydrate
    IM/IV Injection 1 gm/vial Allopathic Third generation Cephalosporins

    Indications

    Urinary tract infection

    Indication detailsView
    Ceftazidime Injection is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases:

    Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp., Haemophilus influenzae, including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis; Escherichia coli; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae; and Staphylococcus aureus (methicillin susceptible strains).

    Skin and Skin Structure Infections caused by Pseudomonas aeruginosa; Klebsiella spp.; Escherichia coli; Proteus spp., including Proteus mirabilis and indole-positive Proteus, Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci).

    Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus, Klebsiella spp.; and Escherichia coli.

    Bacterial Septicemia caused by Pseudomonas aeruginosa, Klebsiella spp., Haemophilus influenzae, Escherichia coli, Serratia spp., Streptococcus pneumoniae and Staphylococcus aureus (methicillin susceptible strains).

    Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin susceptible strains).

    Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli.

    Intraabdominal Infections, including peritonitis caused by Escherichia coli, Klebsiella spp., and Staphylococcus aureus (methicillin susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp.

    Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis, Pseudomonas aeruginosa and Streptococcus pneumoniae.
    Therapeutic classView
    Third generation Cephalosporins
    PharmacologyView
    Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration. Ceftazidime is bactericidal in action exerting its effect by inhibition of enzymes responsible for cell-wall synthesis. A wide range of gram-negative organisms is susceptible to ceftazidime in vitro, including strains resistant to gentamicin and other aminoglycosides. In addition, ceftazidime has been shown to be active against gram-positive organisms. It is highly stable to most clinically important beta-lactamases, plasmid or chromosomal, which are produced by both gram-negative and gram-positive organisms and, consequently, is active against many strains resistant to ampicillin and other cephalosporins.
    DosageView
    The usual adult dosage is 1 gram administered intravenously or intramuscularly every 8 to 12 hours. The dosage and route should be determined by the susceptibility of the causative organisms, the severity of infection and the condition, and renal function of the patient.

    Ceftazidime is to be used by the parenteral route, the dosage depending upon the severity, sensitivity & type of infections and the age, weight & renal function of the patient.

    Adults: The adult dosage range for ceftazidime is 1 to 6 gm per day 8 or 12 hourly (IM/IV) in the majority of infections, 1 gm 8 hourly or 2 gm 12 hourly should be given.
    • In urinary tract infections and many less serious infections: 500 mg or 1 gm 12 hourly is usually adequate.
    • In severe infections, especially immunocompromised patients, including those with neutropenia: 2 gm 8 or 12 hourly should be administered. When used as a prophylactic agent in prostatic surgery 1 gm should be given at the induction of anesthesia. A second dose should be considered at the time of catheter removal.
    Elderly: In view of the reduced clearance of Ceftazidime in acutely ill elderly patients, the daily dosage should not normally exceed 3 gm, especially in those over 80 years of age.
    • Cystic fibrosis: In fibrocystic adults with normal renal function who have pseudomonal lung infections, high doses of 100 to 150 mg/kg/day as three divided doses should be used.
    Infants and Children: The usual dosage range for children aged over two months is 30 to 100 mg/kg/day, given as two or three divided doses. Doses up to 150 mg/kg/day (maximum 6 gm daily) in three divided doses may be given to infected immunocompromised or fibrocystic children or children with meningitis.

    Neonates and Children up to 2 months of age: The usual dosage range is 25 to 60 mg/kg/day as two divided doses.
    AdministrationView
    Ceftazidime may be given intravenously or by deep IM injection into a large muscle mass such as the upper outer quadrant of the gluteus maximus or lateral proof of the thigh. Intra-arterial administration should be avoided. For IV/IM administration, Ceftazidime should be reconstituted with the supplied Sterile Water for Injection.
    Side effectsView
    The most common side-effects are local reactions following IV injection and allergic and gastrointestinal reactions. Hypersensitivity reactions are pruritus, rash, and fever. Angioedema and anaphylaxis have been reported very rarely. Gastrointestinal symptoms are diarrhea, nausea, vomiting, and abdominal pain. Central nervous system reactions included headache, dizziness, and paresthesia.
    ContraindicationsView
    Ceftazidime is contraindicated in patients who have shown hypersensitivity to Ceftazidime or the cephalosporin group of antibiotics.
    PrecautionsView
    The total daily dosage should be reduced when Ceftazidime is administered to patients with renal insufficiency. Ceftazidime should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.
    Pregnancy & lactationView
    Pregnancy: No adequate and well-controlled studies in pregnant women have been conducted with Ceftazidime. Because animal reproduction studies are not always predictive of human response this drug should be used during pregnancy only if clearly needed.

    Lactation: Ceftazidime is excreted in human milk in low concentrations. Because many drugs are excreted in human milk and because the safety of the component of the injections in nursing infants has not been established, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
    Pediatric usageView
    Impaired Renal Function: Ceftazidime is excreted by the kidneys, almost exclusively by glomerular filtration. Therefore, in patients with impaired renal function (glomerular filtration rate <50 mL/min), it is recommended that the dosage of ceftazidime be reduced to compensate for its slower excretion. In patients with suspected renal insufficiency, an initial loading dose of 1 gram of Ceftazidime may be given. An estimate of GFR should be made to determine the appropriate maintenance dosage.

    Dosage in peritoneal dialysis: Ceftazidime may also be used in peritoneal dialysis and continuous ambulatory peritoneal dialysis (CAPD). As well as using Ceftazidime intravenously, it can be incorporated into the dialysis fluid (usually 125 to 250 mg for 2L of dialysis fluid).

    Impaired Hepatic Function: No adjustment in dosage is required for patients with hepatic dysfunction.
    Overdose effectsView
    Ceftazidime overdosage has occurred in patients with renal failure. Reactions have included seizure activity, encephalopathy, asterixis, neuromuscular excitability, and coma. Patients who receive an acute overdosage should be carefully observed and given supportive treatment.
    ReconstitutionView
    Single-dose vial Administration Amount of WFI to be added: 250 mg IM in 1.5 ml, 250 mg IV in 5 ml, 500 mg IM in 1.5 ml, 500 mg IV in 5 ml and 1 g IM in 3 ml, 1 g IV in 10 ml.
    StorageView
    Store below 25°C, protected from light and moisture. Reconstituted solutions are stable for up to 24 h if stored between 2°-8°C.

    Cefazid

    Ceftazidime Pentahydrate
    IM/IV Injection 250 mg/vial Allopathic Third generation Cephalosporins

    Indications

    Urinary tract infection

    Indication detailsView
    Ceftazidime Injection is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases:

    Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp., Haemophilus influenzae, including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis; Escherichia coli; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae; and Staphylococcus aureus (methicillin susceptible strains).

    Skin and Skin Structure Infections caused by Pseudomonas aeruginosa; Klebsiella spp.; Escherichia coli; Proteus spp., including Proteus mirabilis and indole-positive Proteus, Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci).

    Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus, Klebsiella spp.; and Escherichia coli.

    Bacterial Septicemia caused by Pseudomonas aeruginosa, Klebsiella spp., Haemophilus influenzae, Escherichia coli, Serratia spp., Streptococcus pneumoniae and Staphylococcus aureus (methicillin susceptible strains).

    Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin susceptible strains).

    Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli.

    Intraabdominal Infections, including peritonitis caused by Escherichia coli, Klebsiella spp., and Staphylococcus aureus (methicillin susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp.

    Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis, Pseudomonas aeruginosa and Streptococcus pneumoniae.
    Therapeutic classView
    Third generation Cephalosporins
    PharmacologyView
    Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration. Ceftazidime is bactericidal in action exerting its effect by inhibition of enzymes responsible for cell-wall synthesis. A wide range of gram-negative organisms is susceptible to ceftazidime in vitro, including strains resistant to gentamicin and other aminoglycosides. In addition, ceftazidime has been shown to be active against gram-positive organisms. It is highly stable to most clinically important beta-lactamases, plasmid or chromosomal, which are produced by both gram-negative and gram-positive organisms and, consequently, is active against many strains resistant to ampicillin and other cephalosporins.
    DosageView
    The usual adult dosage is 1 gram administered intravenously or intramuscularly every 8 to 12 hours. The dosage and route should be determined by the susceptibility of the causative organisms, the severity of infection and the condition, and renal function of the patient.

    Ceftazidime is to be used by the parenteral route, the dosage depending upon the severity, sensitivity & type of infections and the age, weight & renal function of the patient.

    Adults: The adult dosage range for ceftazidime is 1 to 6 gm per day 8 or 12 hourly (IM/IV) in the majority of infections, 1 gm 8 hourly or 2 gm 12 hourly should be given.
    • In urinary tract infections and many less serious infections: 500 mg or 1 gm 12 hourly is usually adequate.
    • In severe infections, especially immunocompromised patients, including those with neutropenia: 2 gm 8 or 12 hourly should be administered. When used as a prophylactic agent in prostatic surgery 1 gm should be given at the induction of anesthesia. A second dose should be considered at the time of catheter removal.
    Elderly: In view of the reduced clearance of Ceftazidime in acutely ill elderly patients, the daily dosage should not normally exceed 3 gm, especially in those over 80 years of age.
    • Cystic fibrosis: In fibrocystic adults with normal renal function who have pseudomonal lung infections, high doses of 100 to 150 mg/kg/day as three divided doses should be used.
    Infants and Children: The usual dosage range for children aged over two months is 30 to 100 mg/kg/day, given as two or three divided doses. Doses up to 150 mg/kg/day (maximum 6 gm daily) in three divided doses may be given to infected immunocompromised or fibrocystic children or children with meningitis.

    Neonates and Children up to 2 months of age: The usual dosage range is 25 to 60 mg/kg/day as two divided doses.
    AdministrationView
    Ceftazidime may be given intravenously or by deep IM injection into a large muscle mass such as the upper outer quadrant of the gluteus maximus or lateral proof of the thigh. Intra-arterial administration should be avoided. For IV/IM administration, Ceftazidime should be reconstituted with the supplied Sterile Water for Injection.
    Side effectsView
    The most common side-effects are local reactions following IV injection and allergic and gastrointestinal reactions. Hypersensitivity reactions are pruritus, rash, and fever. Angioedema and anaphylaxis have been reported very rarely. Gastrointestinal symptoms are diarrhea, nausea, vomiting, and abdominal pain. Central nervous system reactions included headache, dizziness, and paresthesia.
    ContraindicationsView
    Ceftazidime is contraindicated in patients who have shown hypersensitivity to Ceftazidime or the cephalosporin group of antibiotics.
    PrecautionsView
    The total daily dosage should be reduced when Ceftazidime is administered to patients with renal insufficiency. Ceftazidime should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.
    Pregnancy & lactationView
    Pregnancy: No adequate and well-controlled studies in pregnant women have been conducted with Ceftazidime. Because animal reproduction studies are not always predictive of human response this drug should be used during pregnancy only if clearly needed.

    Lactation: Ceftazidime is excreted in human milk in low concentrations. Because many drugs are excreted in human milk and because the safety of the component of the injections in nursing infants has not been established, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
    Pediatric usageView
    Impaired Renal Function: Ceftazidime is excreted by the kidneys, almost exclusively by glomerular filtration. Therefore, in patients with impaired renal function (glomerular filtration rate <50 mL/min), it is recommended that the dosage of ceftazidime be reduced to compensate for its slower excretion. In patients with suspected renal insufficiency, an initial loading dose of 1 gram of Ceftazidime may be given. An estimate of GFR should be made to determine the appropriate maintenance dosage.

    Dosage in peritoneal dialysis: Ceftazidime may also be used in peritoneal dialysis and continuous ambulatory peritoneal dialysis (CAPD). As well as using Ceftazidime intravenously, it can be incorporated into the dialysis fluid (usually 125 to 250 mg for 2L of dialysis fluid).

    Impaired Hepatic Function: No adjustment in dosage is required for patients with hepatic dysfunction.
    Overdose effectsView
    Ceftazidime overdosage has occurred in patients with renal failure. Reactions have included seizure activity, encephalopathy, asterixis, neuromuscular excitability, and coma. Patients who receive an acute overdosage should be carefully observed and given supportive treatment.
    ReconstitutionView
    Single-dose vial Administration Amount of WFI to be added: 250 mg IM in 1.5 ml, 250 mg IV in 5 ml, 500 mg IM in 1.5 ml, 500 mg IV in 5 ml and 1 g IM in 3 ml, 1 g IV in 10 ml.
    StorageView
    Store below 25°C, protected from light and moisture. Reconstituted solutions are stable for up to 24 h if stored between 2°-8°C.

    Cefazol

    Cefazolin Sodium
    IM/IV Injection 500 mg/vial Allopathic First generation Cephalosporins

    Indications

    Urinary tract infection

    Indication detailsView
    Cefazolin is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections, Urinary Tract Infections, Skin and Skin Structure Infections, Biliary Tract Infections, Bone and Joint Infections, Genital Infections, Septicemia, Endocarditis and Perioperative Prophylaxis.
    Therapeutic classView
    First generation Cephalosporins
    PharmacologyView
    Cefazolin is a 1st generation broad spectrum parenteral Cephalosporin antibiotic.It interferes with the synthesis of bacterial cell wall by inhibiting transpeptidase enzyme. As a result the bacterial cell wall is weakened,the cell swells and then ruptures.
    DosageView
    Adult Dose
    • Moderate to severe infection: 500 mg to 1 gm for every 6 to 8 hours
    • Mild infections caused by susceptible Gram-positive cocci: 250 mg to 500 mg for every 8 hours
    • Acute uncomplicated urinary tract infections: 1 gm for every 12 hours
    • Pneumococcal pneumonia: 500 mg for every 12 hours
    • Severe life-threatening infections (e.g. Endocarditis, Septicemia): 1 gm to 1.5 gm for every 6 hours. In rare instances, doses up to 12 gm per day can be used
    Perioperative Prophylactic Use: To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended doses are:
    • 1 gm IM or IV administered half hour to 1 hour prior to the start of surgery.
    • For lengthy operative procedures (e.g. 2 hours or more), 500 mg to 1 gm IM or IV during surgery.
    • 500 mg to 1 gm IM or IV every 6 to 8 hours for 24 hours postoperatively.
    In surgery where the occurrence of infection may be particularly devastating (e.g. open-heart surgery and prosthetic arthroplasty), the prophylactic administration may be continued for 3 to 5 days following the completion of surgery.
    Side effectsView
    Common side effects include:Injection site reactions (pain, swelling, skin rash, or a hard lump), diarrhea, stomach pain, stomach cramps, nausea, vomiting, loss of appetite, skin rash or itching, hives, white patches or sores inside the mouth or on the lips, vaginal itching or discharge,heartburn, gas,rectal itching,confusion, weakness, hypotension, drowsiness, headache and allergic reactions.
    ContraindicationsView
    Cefazolin is contraindicated in patients with known allergy to the Cephalosporin group of Antibiotics.
    PrecautionsView
    • As with all Cephalosporins, Cefazolin should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly Colitis.
    • As with other β-lactam antibiotics, seizures may occur if inappropriately high doses are administered to patients with impaired renal function.
    InteractionsView
    Probenecid may decrease renal tubular secretion of Cephalosporins when used concurrently, resulting in increased and more prolonged Cephalosporin blood levels.
    Pregnancy & lactationView
    Pregnancy Category B. Cefazolin is present in very low concentrations in the milk of nursing mothers.Caution should be exercised when Cefazolin is administered to a nursing woman.
    Pediatric usageView
    Patients with Impaired Renal Function:
    • Creatinine clearance 35 to 54 ml/min: 1 unit dose (based on unit doses of 500 mg & 1 gm) Every 8 hours
    • Creatinine clearance 11 to 34 ml/min: ½ unit dose (based on unit doses of 500 mg & 1 gm) Every 12 hours
    • Creatinine clearance 10 ml/min: ½ unit dose (based on unit doses of 500 mg & 1 gm) Every 18 to 24 hours
    Patients with Hepatic Insufficiency: No dosage adjustment is necessary in patients with hepatic insufficiency.

    Pediatric Dose: In pediatric patients, a total daily dosage of 25 to 50 mg per kg of body weight, divided into 3 or 4 equal doses, is effective for most mild to moderate infections. Total daily dosage may be increased to 100 mg per kg of body weight for severe infections. Safety for use in premature infants and in neonates has not been established.
    ReconstitutionView
    The content of one vial is to be dissolved in 2 ml (for 500 mg IM/IV Injection) & 2.5 ml (for 1 gm IM/IV Injection) Water for Injection.
    StorageView
    After reconstitution, Cefazolin is stable for 24 hours at room temperature or for 10 days if stored under refrigeration (5°C). Reconstituted solution may range in color from pale yellow to yellow without a change in potency.

    Cefazol

    Cefazolin Sodium
    IM/IV Injection 1 gm/vial Allopathic First generation Cephalosporins

    Indications

    Urinary tract infection

    Indication detailsView
    Cefazolin is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections, Urinary Tract Infections, Skin and Skin Structure Infections, Biliary Tract Infections, Bone and Joint Infections, Genital Infections, Septicemia, Endocarditis and Perioperative Prophylaxis.
    Therapeutic classView
    First generation Cephalosporins
    PharmacologyView
    Cefazolin is a 1st generation broad spectrum parenteral Cephalosporin antibiotic.It interferes with the synthesis of bacterial cell wall by inhibiting transpeptidase enzyme. As a result the bacterial cell wall is weakened,the cell swells and then ruptures.
    DosageView
    Adult Dose
    • Moderate to severe infection: 500 mg to 1 gm for every 6 to 8 hours
    • Mild infections caused by susceptible Gram-positive cocci: 250 mg to 500 mg for every 8 hours
    • Acute uncomplicated urinary tract infections: 1 gm for every 12 hours
    • Pneumococcal pneumonia: 500 mg for every 12 hours
    • Severe life-threatening infections (e.g. Endocarditis, Septicemia): 1 gm to 1.5 gm for every 6 hours. In rare instances, doses up to 12 gm per day can be used
    Perioperative Prophylactic Use: To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended doses are:
    • 1 gm IM or IV administered half hour to 1 hour prior to the start of surgery.
    • For lengthy operative procedures (e.g. 2 hours or more), 500 mg to 1 gm IM or IV during surgery.
    • 500 mg to 1 gm IM or IV every 6 to 8 hours for 24 hours postoperatively.
    In surgery where the occurrence of infection may be particularly devastating (e.g. open-heart surgery and prosthetic arthroplasty), the prophylactic administration may be continued for 3 to 5 days following the completion of surgery.
    Side effectsView
    Common side effects include:Injection site reactions (pain, swelling, skin rash, or a hard lump), diarrhea, stomach pain, stomach cramps, nausea, vomiting, loss of appetite, skin rash or itching, hives, white patches or sores inside the mouth or on the lips, vaginal itching or discharge,heartburn, gas,rectal itching,confusion, weakness, hypotension, drowsiness, headache and allergic reactions.
    ContraindicationsView
    Cefazolin is contraindicated in patients with known allergy to the Cephalosporin group of Antibiotics.
    PrecautionsView
    • As with all Cephalosporins, Cefazolin should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly Colitis.
    • As with other β-lactam antibiotics, seizures may occur if inappropriately high doses are administered to patients with impaired renal function.
    InteractionsView
    Probenecid may decrease renal tubular secretion of Cephalosporins when used concurrently, resulting in increased and more prolonged Cephalosporin blood levels.
    Pregnancy & lactationView
    Pregnancy Category B. Cefazolin is present in very low concentrations in the milk of nursing mothers.Caution should be exercised when Cefazolin is administered to a nursing woman.
    Pediatric usageView
    Patients with Impaired Renal Function:
    • Creatinine clearance 35 to 54 ml/min: 1 unit dose (based on unit doses of 500 mg & 1 gm) Every 8 hours
    • Creatinine clearance 11 to 34 ml/min: ½ unit dose (based on unit doses of 500 mg & 1 gm) Every 12 hours
    • Creatinine clearance 10 ml/min: ½ unit dose (based on unit doses of 500 mg & 1 gm) Every 18 to 24 hours
    Patients with Hepatic Insufficiency: No dosage adjustment is necessary in patients with hepatic insufficiency.

    Pediatric Dose: In pediatric patients, a total daily dosage of 25 to 50 mg per kg of body weight, divided into 3 or 4 equal doses, is effective for most mild to moderate infections. Total daily dosage may be increased to 100 mg per kg of body weight for severe infections. Safety for use in premature infants and in neonates has not been established.
    ReconstitutionView
    The content of one vial is to be dissolved in 2 ml (for 500 mg IM/IV Injection) & 2.5 ml (for 1 gm IM/IV Injection) Water for Injection.
    StorageView
    After reconstitution, Cefazolin is stable for 24 hours at room temperature or for 10 days if stored under refrigeration (5°C). Reconstituted solution may range in color from pale yellow to yellow without a change in potency.

    Cefazone

    Cefoperazone Sodium
    IM/IV Injection 2 gm/vial Allopathic Third generation Cephalosporins

    Indications

    Urinary tract infection

    Indication detailsView
    Cefoperazone is indicated for the treatment of the following infections when caused by susceptible organisms: Respiratory Tract Infections, Peritonitis & Other Intra-abdominal Infections, Bacterial Septicemia, Skin and Skin Structures Infections, Pelvic Inflammatory Disease, Endometritis & Other Infections of the Female Genital Tract, Urinary Tract Infections, Enterococcal Infections etc.
    Therapeutic classView
    Third generation Cephalosporins
    PharmacologyView
    Cefoperazone is a bactericidal Cephalosporin antibiotic which is resistant to most beta-lactamases and active against a wide range of aerobic & anaerobic, Gram positive & Gram negative bacteria. The bactericidal action of Cefoperazone results from the inhibition of bacterial cell wall synthesis. Cefoperazone has a high degree of stability in the presence of beta-lactamases produced by most Gram negative pathogens. Cefoperazone is usually active against organisms which are resistant to other beta-lactam antibiotics because of beta-lactamase production.
    DosageView
    Sterile Cefoperazone Sodium can be administered by IM or IV injection (following dilution).

    Adult: 2 to 4 grams per day administered in equally divided doses every 12 hours. In severe infections or infections caused by less sensitive organisms, the total daily dose and/or frequency may be increased. Patients have been successfully treated with a total daily dosage of 6-12 grams divided into 2,3, or 4 administrations ranging from 1.5 to 4 grams per dose. When treating infections caused by Streptococcus pyogenes, therapy should be continued for at least 10 days.
    Side effectsView
    Hypersensitivity: As with all Cephalosporins, hypersensitivity manifested by skin reactions (1 patient in 45), drug fever (1 in 260), or a change in Coombs’ test (1 in 60) has been reported. These reactions are more likely to occur in patients with a history of allergies, particularly to Penicillin.
    ContraindicationsView
    Cefoperazone is contraindicated in patients with known allergy to the Cephalosporin-class of antibiotics.
    PrecautionsView
    Cefoperazone is extensively excreted in bile. The serum half-life of Cefoperazone is increased 2-4 fold in patients with hepatic disease and/or biliary obstruction. In general, total daily dosage above 4 gm should not be necessary in such patients. If higher dosages are used, serum concentrations should be monitored.
    Pregnancy & lactationView
    Pregnancy Category B.This drug should be used during pregnancy only if clearly needed. Only low concentrations of Cefoperazone is excreted in human milk. Although Cefoperazone passes poorly into breast milk of nursing mothers, caution should be exercised when Cefoperazone is administered to a nursing woman.
    Pediatric usageView
    Children use: Safety and effectiveness in children have not been established.

    Geriatric use: Reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
    ReconstitutionView
    Cefoperazone for intravenous or intramuscular use may be initially reconstituted with compatible solution. Solutions should be allowed to stand after reconstitution to allow any foaming to dissipate to permit visual inspection for complete solubilization. Vigorous and prolonged agitation may be necessary to solubilize Cefoperazone in higher concentrations (above 333 mg Cefoperazone/ml). The maximum solubility of Cefoperazone is approximately 475 mg Cefoperazone/ml of compatible diluent.
    StorageView
    Cefoperazone is to be stored in a dry place, below 25°C and protected from light prior to reconstitution. The reconstituted solution may be stored for 24 hours if kept in room temperature (below 25°C).

    Cefazone

    Cefoperazone Sodium
    IM/IV Injection 1 gm/vial Allopathic Third generation Cephalosporins

    Indications

    Urinary tract infection

    Indication detailsView
    Cefoperazone is indicated for the treatment of the following infections when caused by susceptible organisms: Respiratory Tract Infections, Peritonitis & Other Intra-abdominal Infections, Bacterial Septicemia, Skin and Skin Structures Infections, Pelvic Inflammatory Disease, Endometritis & Other Infections of the Female Genital Tract, Urinary Tract Infections, Enterococcal Infections etc.
    Therapeutic classView
    Third generation Cephalosporins
    PharmacologyView
    Cefoperazone is a bactericidal Cephalosporin antibiotic which is resistant to most beta-lactamases and active against a wide range of aerobic & anaerobic, Gram positive & Gram negative bacteria. The bactericidal action of Cefoperazone results from the inhibition of bacterial cell wall synthesis. Cefoperazone has a high degree of stability in the presence of beta-lactamases produced by most Gram negative pathogens. Cefoperazone is usually active against organisms which are resistant to other beta-lactam antibiotics because of beta-lactamase production.
    DosageView
    Sterile Cefoperazone Sodium can be administered by IM or IV injection (following dilution).

    Adult: 2 to 4 grams per day administered in equally divided doses every 12 hours. In severe infections or infections caused by less sensitive organisms, the total daily dose and/or frequency may be increased. Patients have been successfully treated with a total daily dosage of 6-12 grams divided into 2,3, or 4 administrations ranging from 1.5 to 4 grams per dose. When treating infections caused by Streptococcus pyogenes, therapy should be continued for at least 10 days.
    Side effectsView
    Hypersensitivity: As with all Cephalosporins, hypersensitivity manifested by skin reactions (1 patient in 45), drug fever (1 in 260), or a change in Coombs’ test (1 in 60) has been reported. These reactions are more likely to occur in patients with a history of allergies, particularly to Penicillin.
    ContraindicationsView
    Cefoperazone is contraindicated in patients with known allergy to the Cephalosporin-class of antibiotics.
    PrecautionsView
    Cefoperazone is extensively excreted in bile. The serum half-life of Cefoperazone is increased 2-4 fold in patients with hepatic disease and/or biliary obstruction. In general, total daily dosage above 4 gm should not be necessary in such patients. If higher dosages are used, serum concentrations should be monitored.
    Pregnancy & lactationView
    Pregnancy Category B.This drug should be used during pregnancy only if clearly needed. Only low concentrations of Cefoperazone is excreted in human milk. Although Cefoperazone passes poorly into breast milk of nursing mothers, caution should be exercised when Cefoperazone is administered to a nursing woman.
    Pediatric usageView
    Children use: Safety and effectiveness in children have not been established.

    Geriatric use: Reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
    ReconstitutionView
    Cefoperazone for intravenous or intramuscular use may be initially reconstituted with compatible solution. Solutions should be allowed to stand after reconstitution to allow any foaming to dissipate to permit visual inspection for complete solubilization. Vigorous and prolonged agitation may be necessary to solubilize Cefoperazone in higher concentrations (above 333 mg Cefoperazone/ml). The maximum solubility of Cefoperazone is approximately 475 mg Cefoperazone/ml of compatible diluent.
    StorageView
    Cefoperazone is to be stored in a dry place, below 25°C and protected from light prior to reconstitution. The reconstituted solution may be stored for 24 hours if kept in room temperature (below 25°C).

    Cefcare

    Cefadroxil Monohydrate
    Capsule 500 mg Allopathic First generation Cephalosporins

    Indications

    Urinary tract infection

    Indication detailsView
    It is indicated for the treatment of upper respiratory tract infections (pharyngitis and tonsillitis) caused by Streptococcus pyogenes (group-A beta-hemolytic Streptococci) and Streptococcus pneumoniae; urinary tract infections caused by E. coli, Proteus mirabilis, and Klebsiella species and skin & soft tissue infections caused by Staphylococci (including penicillinase producing bacteria) and Streptococci.
    Therapeutic classView
    First generation Cephalosporins
    PharmacologyView
    Cefadroxil inhibits bacterial cell wall synthesis by binding to 1 or more of the penicillin-binding proteins (PBPs) which in turn inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
    DosageView
    Adult:
    • Pharyngitis and Tonsillitis: 1 g per day in one or two divided doses.
    • Urinary Tract Infections: 1 or 2 g per day in one or two divided doses.
    • Skin and Skin Structure Infections: 1 g per day in one or two divided doses.
    Children: 30 mg/kg daily in divided doses every 12 hours.

    It may be taken with meals or on empty stomach. Administration with food may be helpful in diminishing potential gastrointestinal complaints.
    Side effectsView
    Generally Cefadroxil is well tolerated. However, the most commonly reported side effects are gastrointestinal disturbances and hypersensitivity phenomena.
    ContraindicationsView
    Cefadroxil is contraindicated in patients with a history of hypersensitivity to Cefadroxil or any of the ingredients of it.
    PrecautionsView
    Use of this antibiotic may cause pseudomembranous colitis; so caution should be taken during diagnosis in patients who develop diarrhea in association with Cefadroxil therapy.
    InteractionsView
    There is no significant drug interaction with other drugs.
    Pregnancy & lactationView
    US FDA pregnancy category of Cefadroxil is B. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Cefadroxil have been shown to be excreted in human milk. So, caution should be exercised when Cefadroxil is administered during lactation.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Cefcare

    Cefadroxil Monohydrate
    Pediatric Drops 125 mg/1.25 ml Allopathic First generation Cephalosporins

    Indications

    Urinary tract infection

    Indication detailsView
    It is indicated for the treatment of upper respiratory tract infections (pharyngitis and tonsillitis) caused by Streptococcus pyogenes (group-A beta-hemolytic Streptococci) and Streptococcus pneumoniae; urinary tract infections caused by E. coli, Proteus mirabilis, and Klebsiella species and skin & soft tissue infections caused by Staphylococci (including penicillinase producing bacteria) and Streptococci.
    Therapeutic classView
    First generation Cephalosporins
    PharmacologyView
    Cefadroxil inhibits bacterial cell wall synthesis by binding to 1 or more of the penicillin-binding proteins (PBPs) which in turn inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
    DosageView
    Adult:
    • Pharyngitis and Tonsillitis: 1 g per day in one or two divided doses.
    • Urinary Tract Infections: 1 or 2 g per day in one or two divided doses.
    • Skin and Skin Structure Infections: 1 g per day in one or two divided doses.
    Children: 30 mg/kg daily in divided doses every 12 hours.

    It may be taken with meals or on empty stomach. Administration with food may be helpful in diminishing potential gastrointestinal complaints.
    Side effectsView
    Generally Cefadroxil is well tolerated. However, the most commonly reported side effects are gastrointestinal disturbances and hypersensitivity phenomena.
    ContraindicationsView
    Cefadroxil is contraindicated in patients with a history of hypersensitivity to Cefadroxil or any of the ingredients of it.
    PrecautionsView
    Use of this antibiotic may cause pseudomembranous colitis; so caution should be taken during diagnosis in patients who develop diarrhea in association with Cefadroxil therapy.
    InteractionsView
    There is no significant drug interaction with other drugs.
    Pregnancy & lactationView
    US FDA pregnancy category of Cefadroxil is B. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Cefadroxil have been shown to be excreted in human milk. So, caution should be exercised when Cefadroxil is administered during lactation.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Cefcare

    Cefadroxil Monohydrate
    Powder for Suspension 125 mg/5 ml Allopathic First generation Cephalosporins

    Indications

    Urinary tract infection

    Indication detailsView
    It is indicated for the treatment of upper respiratory tract infections (pharyngitis and tonsillitis) caused by Streptococcus pyogenes (group-A beta-hemolytic Streptococci) and Streptococcus pneumoniae; urinary tract infections caused by E. coli, Proteus mirabilis, and Klebsiella species and skin & soft tissue infections caused by Staphylococci (including penicillinase producing bacteria) and Streptococci.
    Therapeutic classView
    First generation Cephalosporins
    PharmacologyView
    Cefadroxil inhibits bacterial cell wall synthesis by binding to 1 or more of the penicillin-binding proteins (PBPs) which in turn inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
    DosageView
    Adult:
    • Pharyngitis and Tonsillitis: 1 g per day in one or two divided doses.
    • Urinary Tract Infections: 1 or 2 g per day in one or two divided doses.
    • Skin and Skin Structure Infections: 1 g per day in one or two divided doses.
    Children: 30 mg/kg daily in divided doses every 12 hours.

    It may be taken with meals or on empty stomach. Administration with food may be helpful in diminishing potential gastrointestinal complaints.
    Side effectsView
    Generally Cefadroxil is well tolerated. However, the most commonly reported side effects are gastrointestinal disturbances and hypersensitivity phenomena.
    ContraindicationsView
    Cefadroxil is contraindicated in patients with a history of hypersensitivity to Cefadroxil or any of the ingredients of it.
    PrecautionsView
    Use of this antibiotic may cause pseudomembranous colitis; so caution should be taken during diagnosis in patients who develop diarrhea in association with Cefadroxil therapy.
    InteractionsView
    There is no significant drug interaction with other drugs.
    Pregnancy & lactationView
    US FDA pregnancy category of Cefadroxil is B. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Cefadroxil have been shown to be excreted in human milk. So, caution should be exercised when Cefadroxil is administered during lactation.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Cefdiren

    Cefditoren
    Tablet 200 mg Allopathic Third generation Cephalosporins

    Indications

    Tonsillitis

    Indication detailsView
    Cefditoren is indicated for the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the conditions listed below:
    • Acute Bacterial Exacerbation of Chronic Bronchitis
    • Community Acquired Pneumonia
    • Pharyngitis
    • Tonsillitis
    • Uncomplicated Skin and Skin-Structure Infections
    Therapeutic classView
    Third generation Cephalosporins
    PharmacologyView
    Cefditoren is a preparation of Cefditoren Pivoxil which is a broad spectrum third generation cephalosporin antibiotic. Cefditoren is a prodrug which is hydrolyzed by esterases during absorption, and the drug is distributed in the circulating blood as active Cefditoren. Cefditoren has antibacterial activity against gram-positive and gram-negative pathogens. The bactericidal activity of Cefditoren results from the inhibition of cell wall synthesis via affinity for penicillin- binding proteins (PBPs). Cefditoren is stable in the presence of a variety of ß-lactamases, including penicillinases and some cephalosporinases.
    DosageView
    Cefditoren should be taken after meals.

    Community-Acquired Pneumonia    : 400 mg twice daily for 14 days.
    Acute Exacerbation of Chronic Bronchitis: 400 mg twice daily for 10 days.
    Pharyngotonsillitis and Acute Sinusitis: 200 mg twice daily for 10 days.
    Uncomplicated Skin and Soft Structure Infections: 200 mg twice daily for 10 days.
    Side effectsView
    The most common side effects of Cefditoren are diarrhea, nausea, headache, abdominal pain, vaginal moniliasis, dyspepsia, vomiting, abnormal dreams, allergic reaction, anorexia, constipation, dizziness, dry mouth and fever.
    ContraindicationsView
    Cefditoren is contraindicated in patients with known allergy to the cephalosporin class of antibiotics or any of its components. Cefditoren contain sodium caseinate, a milk protein. Patients with milk protein hypersensitivity (not lactose intolerance) should not be administered Cefditoren.
    PrecautionsView
    Cefditoren is not recommended when prolonged antibiotic treatment is necessary, since other pivalate-containing compounds have caused clinical manifestations of carnitine deficiency when used over a period of months. Prescribing Cefditoren in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
    InteractionsView
    Antacids and Famotidine (intravenous administration) reduced the oral absorption of Cefditoren. As with other ß-lactam antibiotics, co-administration of probenecid with Cefditoren Pivoxil resulted in an increase in the plasma exposure of Cefditoren. Multiple doses of Cefditoren had no effect on the pharmacokinetics of ethinyl estradiol, the estrogenic component in most oral contraceptives.
    Pregnancy & lactationView
    Pregnancy category B. There are no adequate and well-controlled studies in pregnant women. Cefditoren should be used during pregnancy only if clearly needed. Animal studies show that Cefditoren excreted in breast milk. Caution should be exercised when Cefditoren is administered to nursing women.
    Pediatric usageView
    Children: Use of Cefditoren is not recommended for pediatric patients less than 12 years of age. The safety and efficacy of Cefditoren tablets in this population, including any effects of altered carnitine concentration, have not been established.

    Geriatric: No dose adjustments are necessary in geriatric patients with normal (for their age) renal function.

    Patients with renal insufficiency: No dose adjustment is necessary for patients with mild renal impairment (ClCr: 50-80 mL/min/1.73 m2). It is recommended that not more than 200 mg BID be administered to patients with moderate renal impairment (ClCr: 30-49 mL/min/1.73 m2) and 200 mg QD be administered to patients with severe renal impairment (ClCr: <30 mL/min/1.73 m2 ). The appropriate dose in patients with end-stage renal disease has not been determined.

    Patients with hepatic disease: No dose adjustments are necessary for patients with mild or moderate hepatic impairment.
    Overdose effectsView
    Information on Cefditoren overdosage in humans is not available. However, with other ß-lactam antibiotics, adverse effects following overdosage have included nausea, vomiting, epigastric distress, diarrhea, and convulsions. Hemodialysis may aid in the removal of Cefditoren from the body, particularly if renal function is compromised.
    StorageView
    Store in a cool (below 25°C) and dry place protected from light.

    Cefdiren

    Cefditoren
    Tablet 400 mg Allopathic Third generation Cephalosporins

    Indications

    Tonsillitis

    Indication detailsView
    Cefditoren is indicated for the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the conditions listed below:
    • Acute Bacterial Exacerbation of Chronic Bronchitis
    • Community Acquired Pneumonia
    • Pharyngitis
    • Tonsillitis
    • Uncomplicated Skin and Skin-Structure Infections
    Therapeutic classView
    Third generation Cephalosporins
    PharmacologyView
    Cefditoren is a preparation of Cefditoren Pivoxil which is a broad spectrum third generation cephalosporin antibiotic. Cefditoren is a prodrug which is hydrolyzed by esterases during absorption, and the drug is distributed in the circulating blood as active Cefditoren. Cefditoren has antibacterial activity against gram-positive and gram-negative pathogens. The bactericidal activity of Cefditoren results from the inhibition of cell wall synthesis via affinity for penicillin- binding proteins (PBPs). Cefditoren is stable in the presence of a variety of ß-lactamases, including penicillinases and some cephalosporinases.
    DosageView
    Cefditoren should be taken after meals.

    Community-Acquired Pneumonia    : 400 mg twice daily for 14 days.
    Acute Exacerbation of Chronic Bronchitis: 400 mg twice daily for 10 days.
    Pharyngotonsillitis and Acute Sinusitis: 200 mg twice daily for 10 days.
    Uncomplicated Skin and Soft Structure Infections: 200 mg twice daily for 10 days.
    Side effectsView
    The most common side effects of Cefditoren are diarrhea, nausea, headache, abdominal pain, vaginal moniliasis, dyspepsia, vomiting, abnormal dreams, allergic reaction, anorexia, constipation, dizziness, dry mouth and fever.
    ContraindicationsView
    Cefditoren is contraindicated in patients with known allergy to the cephalosporin class of antibiotics or any of its components. Cefditoren contain sodium caseinate, a milk protein. Patients with milk protein hypersensitivity (not lactose intolerance) should not be administered Cefditoren.
    PrecautionsView
    Cefditoren is not recommended when prolonged antibiotic treatment is necessary, since other pivalate-containing compounds have caused clinical manifestations of carnitine deficiency when used over a period of months. Prescribing Cefditoren in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
    InteractionsView
    Antacids and Famotidine (intravenous administration) reduced the oral absorption of Cefditoren. As with other ß-lactam antibiotics, co-administration of probenecid with Cefditoren Pivoxil resulted in an increase in the plasma exposure of Cefditoren. Multiple doses of Cefditoren had no effect on the pharmacokinetics of ethinyl estradiol, the estrogenic component in most oral contraceptives.
    Pregnancy & lactationView
    Pregnancy category B. There are no adequate and well-controlled studies in pregnant women. Cefditoren should be used during pregnancy only if clearly needed. Animal studies show that Cefditoren excreted in breast milk. Caution should be exercised when Cefditoren is administered to nursing women.
    Pediatric usageView
    Children: Use of Cefditoren is not recommended for pediatric patients less than 12 years of age. The safety and efficacy of Cefditoren tablets in this population, including any effects of altered carnitine concentration, have not been established.

    Geriatric: No dose adjustments are necessary in geriatric patients with normal (for their age) renal function.

    Patients with renal insufficiency: No dose adjustment is necessary for patients with mild renal impairment (ClCr: 50-80 mL/min/1.73 m2). It is recommended that not more than 200 mg BID be administered to patients with moderate renal impairment (ClCr: 30-49 mL/min/1.73 m2) and 200 mg QD be administered to patients with severe renal impairment (ClCr: <30 mL/min/1.73 m2 ). The appropriate dose in patients with end-stage renal disease has not been determined.

    Patients with hepatic disease: No dose adjustments are necessary for patients with mild or moderate hepatic impairment.
    Overdose effectsView
    Information on Cefditoren overdosage in humans is not available. However, with other ß-lactam antibiotics, adverse effects following overdosage have included nausea, vomiting, epigastric distress, diarrhea, and convulsions. Hemodialysis may aid in the removal of Cefditoren from the body, particularly if renal function is compromised.
    StorageView
    Store in a cool (below 25°C) and dry place protected from light.

    Cefditor

    Cefditoren
    Tablet 400 mg Allopathic Third generation Cephalosporins

    Indications

    Tonsillitis

    Indication detailsView
    Cefditoren is indicated for the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the conditions listed below:
    • Acute Bacterial Exacerbation of Chronic Bronchitis
    • Community Acquired Pneumonia
    • Pharyngitis
    • Tonsillitis
    • Uncomplicated Skin and Skin-Structure Infections
    Therapeutic classView
    Third generation Cephalosporins
    PharmacologyView
    Cefditoren is a preparation of Cefditoren Pivoxil which is a broad spectrum third generation cephalosporin antibiotic. Cefditoren is a prodrug which is hydrolyzed by esterases during absorption, and the drug is distributed in the circulating blood as active Cefditoren. Cefditoren has antibacterial activity against gram-positive and gram-negative pathogens. The bactericidal activity of Cefditoren results from the inhibition of cell wall synthesis via affinity for penicillin- binding proteins (PBPs). Cefditoren is stable in the presence of a variety of ß-lactamases, including penicillinases and some cephalosporinases.
    DosageView
    Cefditoren should be taken after meals.

    Community-Acquired Pneumonia    : 400 mg twice daily for 14 days.
    Acute Exacerbation of Chronic Bronchitis: 400 mg twice daily for 10 days.
    Pharyngotonsillitis and Acute Sinusitis: 200 mg twice daily for 10 days.
    Uncomplicated Skin and Soft Structure Infections: 200 mg twice daily for 10 days.
    Side effectsView
    The most common side effects of Cefditoren are diarrhea, nausea, headache, abdominal pain, vaginal moniliasis, dyspepsia, vomiting, abnormal dreams, allergic reaction, anorexia, constipation, dizziness, dry mouth and fever.
    ContraindicationsView
    Cefditoren is contraindicated in patients with known allergy to the cephalosporin class of antibiotics or any of its components. Cefditoren contain sodium caseinate, a milk protein. Patients with milk protein hypersensitivity (not lactose intolerance) should not be administered Cefditoren.
    PrecautionsView
    Cefditoren is not recommended when prolonged antibiotic treatment is necessary, since other pivalate-containing compounds have caused clinical manifestations of carnitine deficiency when used over a period of months. Prescribing Cefditoren in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
    InteractionsView
    Antacids and Famotidine (intravenous administration) reduced the oral absorption of Cefditoren. As with other ß-lactam antibiotics, co-administration of probenecid with Cefditoren Pivoxil resulted in an increase in the plasma exposure of Cefditoren. Multiple doses of Cefditoren had no effect on the pharmacokinetics of ethinyl estradiol, the estrogenic component in most oral contraceptives.
    Pregnancy & lactationView
    Pregnancy category B. There are no adequate and well-controlled studies in pregnant women. Cefditoren should be used during pregnancy only if clearly needed. Animal studies show that Cefditoren excreted in breast milk. Caution should be exercised when Cefditoren is administered to nursing women.
    Pediatric usageView
    Children: Use of Cefditoren is not recommended for pediatric patients less than 12 years of age. The safety and efficacy of Cefditoren tablets in this population, including any effects of altered carnitine concentration, have not been established.

    Geriatric: No dose adjustments are necessary in geriatric patients with normal (for their age) renal function.

    Patients with renal insufficiency: No dose adjustment is necessary for patients with mild renal impairment (ClCr: 50-80 mL/min/1.73 m2). It is recommended that not more than 200 mg BID be administered to patients with moderate renal impairment (ClCr: 30-49 mL/min/1.73 m2) and 200 mg QD be administered to patients with severe renal impairment (ClCr: <30 mL/min/1.73 m2 ). The appropriate dose in patients with end-stage renal disease has not been determined.

    Patients with hepatic disease: No dose adjustments are necessary for patients with mild or moderate hepatic impairment.
    Overdose effectsView
    Information on Cefditoren overdosage in humans is not available. However, with other ß-lactam antibiotics, adverse effects following overdosage have included nausea, vomiting, epigastric distress, diarrhea, and convulsions. Hemodialysis may aid in the removal of Cefditoren from the body, particularly if renal function is compromised.
    StorageView
    Store in a cool (below 25°C) and dry place protected from light.

    Cefditor

    Cefditoren
    Tablet 200 mg Allopathic Third generation Cephalosporins

    Indications

    Tonsillitis

    Indication detailsView
    Cefditoren is indicated for the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the conditions listed below:
    • Acute Bacterial Exacerbation of Chronic Bronchitis
    • Community Acquired Pneumonia
    • Pharyngitis
    • Tonsillitis
    • Uncomplicated Skin and Skin-Structure Infections
    Therapeutic classView
    Third generation Cephalosporins
    PharmacologyView
    Cefditoren is a preparation of Cefditoren Pivoxil which is a broad spectrum third generation cephalosporin antibiotic. Cefditoren is a prodrug which is hydrolyzed by esterases during absorption, and the drug is distributed in the circulating blood as active Cefditoren. Cefditoren has antibacterial activity against gram-positive and gram-negative pathogens. The bactericidal activity of Cefditoren results from the inhibition of cell wall synthesis via affinity for penicillin- binding proteins (PBPs). Cefditoren is stable in the presence of a variety of ß-lactamases, including penicillinases and some cephalosporinases.
    DosageView
    Cefditoren should be taken after meals.

    Community-Acquired Pneumonia    : 400 mg twice daily for 14 days.
    Acute Exacerbation of Chronic Bronchitis: 400 mg twice daily for 10 days.
    Pharyngotonsillitis and Acute Sinusitis: 200 mg twice daily for 10 days.
    Uncomplicated Skin and Soft Structure Infections: 200 mg twice daily for 10 days.
    Side effectsView
    The most common side effects of Cefditoren are diarrhea, nausea, headache, abdominal pain, vaginal moniliasis, dyspepsia, vomiting, abnormal dreams, allergic reaction, anorexia, constipation, dizziness, dry mouth and fever.
    ContraindicationsView
    Cefditoren is contraindicated in patients with known allergy to the cephalosporin class of antibiotics or any of its components. Cefditoren contain sodium caseinate, a milk protein. Patients with milk protein hypersensitivity (not lactose intolerance) should not be administered Cefditoren.
    PrecautionsView
    Cefditoren is not recommended when prolonged antibiotic treatment is necessary, since other pivalate-containing compounds have caused clinical manifestations of carnitine deficiency when used over a period of months. Prescribing Cefditoren in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
    InteractionsView
    Antacids and Famotidine (intravenous administration) reduced the oral absorption of Cefditoren. As with other ß-lactam antibiotics, co-administration of probenecid with Cefditoren Pivoxil resulted in an increase in the plasma exposure of Cefditoren. Multiple doses of Cefditoren had no effect on the pharmacokinetics of ethinyl estradiol, the estrogenic component in most oral contraceptives.
    Pregnancy & lactationView
    Pregnancy category B. There are no adequate and well-controlled studies in pregnant women. Cefditoren should be used during pregnancy only if clearly needed. Animal studies show that Cefditoren excreted in breast milk. Caution should be exercised when Cefditoren is administered to nursing women.
    Pediatric usageView
    Children: Use of Cefditoren is not recommended for pediatric patients less than 12 years of age. The safety and efficacy of Cefditoren tablets in this population, including any effects of altered carnitine concentration, have not been established.

    Geriatric: No dose adjustments are necessary in geriatric patients with normal (for their age) renal function.

    Patients with renal insufficiency: No dose adjustment is necessary for patients with mild renal impairment (ClCr: 50-80 mL/min/1.73 m2). It is recommended that not more than 200 mg BID be administered to patients with moderate renal impairment (ClCr: 30-49 mL/min/1.73 m2) and 200 mg QD be administered to patients with severe renal impairment (ClCr: <30 mL/min/1.73 m2 ). The appropriate dose in patients with end-stage renal disease has not been determined.

    Patients with hepatic disease: No dose adjustments are necessary for patients with mild or moderate hepatic impairment.
    Overdose effectsView
    Information on Cefditoren overdosage in humans is not available. However, with other ß-lactam antibiotics, adverse effects following overdosage have included nausea, vomiting, epigastric distress, diarrhea, and convulsions. Hemodialysis may aid in the removal of Cefditoren from the body, particularly if renal function is compromised.
    StorageView
    Store in a cool (below 25°C) and dry place protected from light.

    Cefdox

    Cefpodoxime Proxetil
    Powder for Suspension 40 mg/5 ml Allopathic Third generation Cephalosporins

    Indications

    Urinary tract infection

    Indication detailsView
    Cefpodoxime is indicated for the treatment of infections caused by susceptible microorganism, listed below:
    • Acute otitis media caused by Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenza, Moraxella catarrhalis (including beta-lactamase producing strains).
    • Pharyngitis/tonsillitis caused by Streptococcus pyogenes.
    • Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase producing strains), Streptococcus pneumoniae and Moraxella catarrhalis.
    • Community acquired pneumonia caused by S. pneumoniae or H. influenza (including beta-lactamase-producing strains).
    • Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae (non-beta-lactamase-producing strains only), or M. catarrhalis.
    • Skin and skin structure infections caused by Staphylococcus aureus, Streptococcus pyogenes.
    • Uncomplicated urinary tract infections caused by E. coli, Klebsiella pneumoniae, Proteus mirabilis or Staphylococcus saprophyticus.
    • Uncomplicated gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains).
    • Rectal gonococcal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains).
    Therapeutic classView
    Third generation Cephalosporins
    PharmacologyView
    Cefpodoxime is an oral 3rd generation cephalosporin, which has good stability to beta lactamases and activity against Gram negative and Gram positive bacteria. It is indicated for the treatment of infections either before the infecting organism has been identified. It is a prodrug its active metabolite is Cefpodoxime. Approximately 29 to 33% of Cefpodoxime excreted unchanged in the urine in 12 hours.
    DosageView
    Adults and Adolescents (13 years and older)
    • Pharyngitis/tonsillitis: 100 mg 12 hourly, 5 to 10 days
    • Acute maxillary sinusitis: 200 mg 12 hourly, 10 day
    • Community acquired pneumonia: 200 mg 12 hourly, 14 days
    • Acute bacterial exacerbations of chronic bronchitis: 200 mg 12 hourly, 10 days
    • Skin and skin structure: 400 mg 12 hourly, 7 to 14 days
    • Uncomplicated urinary tract infection: 100 mg 12 hourly, 7 days
    • Uncomplicated gonorrhea: single dose of 200 mg
    • Rectal gonococcal infections in women: single dose of 200 mg
    Infants and Pediatric Patients (2 months to 12 years)
    • Acute otitis media: 5 mg/kg body weight 12 hourly, 5 days
    • Pharyngitis /tonsillitis: 5 mg/kg body weight 12 hourly, 5 to 10 days
    • Acute maxillary sinusitis: 5 mg/kg body weight 12 hourly, 10 days
    Side effectsView
    Cefpodoxime has very few side effects. Possible side effects include gastrointestinal disorders (such as- diarrhea, nausea, vomiting and abdominal pain), rash, urticaria and itching.
    ContraindicationsView
    Cefpodoxime is contraindicated in patients with known allergy to cephalosporins.
    PrecautionsView
    In patients with transient or persistent reduction in urinary output due to renal insufficiency, the total daily dose of Cefpodoxime should be reduced. Cefpodoxime should be administered with caution to patients receiving concurrent treatment with potent diuretics. As with other antibiotics, prolonged use of Cefpodoxime may result in overgrowth of non-susceptible organisms.
    InteractionsView
    Cefpodoxime concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H2 blockers reduces peak plasma levels and the extent of absorption respectively. Renal excretion of Cefpodoxime is inhibit by probenecid.
    Pregnancy & lactationView
    US FDA pregnancy category of Cefpodoxime is B. There is, however, no adequate and well-controlled study in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Cefpodoxime have been shown to be excreted in human milk. So, caution should be exercised when Cefpodoxime is administered to a nursing woman.
    Pediatric usageView
    Patients with severe renal impairment (creatinin clearance <30 ml/min) the dosing intervals should be increased to 24 hourly. The dosage adjustment is not require in cases of hepatic impairment.
    ReconstitutionView
    Step 1: Shake the bottle well to loosen the powder.
    Step 2    : Add boiled and cooled water in the bottle.
    Step 3    : Shake until powder is completely mixed with water.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Cefdox

    Cefpodoxime Proxetil
    Pediatric Drops 20 mg/ml Allopathic Third generation Cephalosporins

    Indications

    Urinary tract infection

    Indication detailsView
    Cefpodoxime is indicated for the treatment of infections caused by susceptible microorganism, listed below:
    • Acute otitis media caused by Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenza, Moraxella catarrhalis (including beta-lactamase producing strains).
    • Pharyngitis/tonsillitis caused by Streptococcus pyogenes.
    • Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase producing strains), Streptococcus pneumoniae and Moraxella catarrhalis.
    • Community acquired pneumonia caused by S. pneumoniae or H. influenza (including beta-lactamase-producing strains).
    • Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae (non-beta-lactamase-producing strains only), or M. catarrhalis.
    • Skin and skin structure infections caused by Staphylococcus aureus, Streptococcus pyogenes.
    • Uncomplicated urinary tract infections caused by E. coli, Klebsiella pneumoniae, Proteus mirabilis or Staphylococcus saprophyticus.
    • Uncomplicated gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains).
    • Rectal gonococcal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains).
    Therapeutic classView
    Third generation Cephalosporins
    PharmacologyView
    Cefpodoxime is an oral 3rd generation cephalosporin, which has good stability to beta lactamases and activity against Gram negative and Gram positive bacteria. It is indicated for the treatment of infections either before the infecting organism has been identified. It is a prodrug its active metabolite is Cefpodoxime. Approximately 29 to 33% of Cefpodoxime excreted unchanged in the urine in 12 hours.
    DosageView
    Adults and Adolescents (13 years and older)
    • Pharyngitis/tonsillitis: 100 mg 12 hourly, 5 to 10 days
    • Acute maxillary sinusitis: 200 mg 12 hourly, 10 day
    • Community acquired pneumonia: 200 mg 12 hourly, 14 days
    • Acute bacterial exacerbations of chronic bronchitis: 200 mg 12 hourly, 10 days
    • Skin and skin structure: 400 mg 12 hourly, 7 to 14 days
    • Uncomplicated urinary tract infection: 100 mg 12 hourly, 7 days
    • Uncomplicated gonorrhea: single dose of 200 mg
    • Rectal gonococcal infections in women: single dose of 200 mg
    Infants and Pediatric Patients (2 months to 12 years)
    • Acute otitis media: 5 mg/kg body weight 12 hourly, 5 days
    • Pharyngitis /tonsillitis: 5 mg/kg body weight 12 hourly, 5 to 10 days
    • Acute maxillary sinusitis: 5 mg/kg body weight 12 hourly, 10 days
    Side effectsView
    Cefpodoxime has very few side effects. Possible side effects include gastrointestinal disorders (such as- diarrhea, nausea, vomiting and abdominal pain), rash, urticaria and itching.
    ContraindicationsView
    Cefpodoxime is contraindicated in patients with known allergy to cephalosporins.
    PrecautionsView
    In patients with transient or persistent reduction in urinary output due to renal insufficiency, the total daily dose of Cefpodoxime should be reduced. Cefpodoxime should be administered with caution to patients receiving concurrent treatment with potent diuretics. As with other antibiotics, prolonged use of Cefpodoxime may result in overgrowth of non-susceptible organisms.
    InteractionsView
    Cefpodoxime concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H2 blockers reduces peak plasma levels and the extent of absorption respectively. Renal excretion of Cefpodoxime is inhibit by probenecid.
    Pregnancy & lactationView
    US FDA pregnancy category of Cefpodoxime is B. There is, however, no adequate and well-controlled study in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Cefpodoxime have been shown to be excreted in human milk. So, caution should be exercised when Cefpodoxime is administered to a nursing woman.
    Pediatric usageView
    Patients with severe renal impairment (creatinin clearance <30 ml/min) the dosing intervals should be increased to 24 hourly. The dosage adjustment is not require in cases of hepatic impairment.
    ReconstitutionView
    Step 1: Shake the bottle well to loosen the powder.
    Step 2    : Add boiled and cooled water in the bottle.
    Step 3    : Shake until powder is completely mixed with water.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Cefdox

    Cefpodoxime Proxetil
    Capsule 100 mg Allopathic Third generation Cephalosporins

    Indications

    Urinary tract infection

    Indication detailsView
    Cefpodoxime is indicated for the treatment of infections caused by susceptible microorganism, listed below:
    • Acute otitis media caused by Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenza, Moraxella catarrhalis (including beta-lactamase producing strains).
    • Pharyngitis/tonsillitis caused by Streptococcus pyogenes.
    • Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase producing strains), Streptococcus pneumoniae and Moraxella catarrhalis.
    • Community acquired pneumonia caused by S. pneumoniae or H. influenza (including beta-lactamase-producing strains).
    • Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae (non-beta-lactamase-producing strains only), or M. catarrhalis.
    • Skin and skin structure infections caused by Staphylococcus aureus, Streptococcus pyogenes.
    • Uncomplicated urinary tract infections caused by E. coli, Klebsiella pneumoniae, Proteus mirabilis or Staphylococcus saprophyticus.
    • Uncomplicated gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains).
    • Rectal gonococcal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains).
    Therapeutic classView
    Third generation Cephalosporins
    PharmacologyView
    Cefpodoxime is an oral 3rd generation cephalosporin, which has good stability to beta lactamases and activity against Gram negative and Gram positive bacteria. It is indicated for the treatment of infections either before the infecting organism has been identified. It is a prodrug its active metabolite is Cefpodoxime. Approximately 29 to 33% of Cefpodoxime excreted unchanged in the urine in 12 hours.
    DosageView
    Adults and Adolescents (13 years and older)
    • Pharyngitis/tonsillitis: 100 mg 12 hourly, 5 to 10 days
    • Acute maxillary sinusitis: 200 mg 12 hourly, 10 day
    • Community acquired pneumonia: 200 mg 12 hourly, 14 days
    • Acute bacterial exacerbations of chronic bronchitis: 200 mg 12 hourly, 10 days
    • Skin and skin structure: 400 mg 12 hourly, 7 to 14 days
    • Uncomplicated urinary tract infection: 100 mg 12 hourly, 7 days
    • Uncomplicated gonorrhea: single dose of 200 mg
    • Rectal gonococcal infections in women: single dose of 200 mg
    Infants and Pediatric Patients (2 months to 12 years)
    • Acute otitis media: 5 mg/kg body weight 12 hourly, 5 days
    • Pharyngitis /tonsillitis: 5 mg/kg body weight 12 hourly, 5 to 10 days
    • Acute maxillary sinusitis: 5 mg/kg body weight 12 hourly, 10 days
    Side effectsView
    Cefpodoxime has very few side effects. Possible side effects include gastrointestinal disorders (such as- diarrhea, nausea, vomiting and abdominal pain), rash, urticaria and itching.
    ContraindicationsView
    Cefpodoxime is contraindicated in patients with known allergy to cephalosporins.
    PrecautionsView
    In patients with transient or persistent reduction in urinary output due to renal insufficiency, the total daily dose of Cefpodoxime should be reduced. Cefpodoxime should be administered with caution to patients receiving concurrent treatment with potent diuretics. As with other antibiotics, prolonged use of Cefpodoxime may result in overgrowth of non-susceptible organisms.
    InteractionsView
    Cefpodoxime concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H2 blockers reduces peak plasma levels and the extent of absorption respectively. Renal excretion of Cefpodoxime is inhibit by probenecid.
    Pregnancy & lactationView
    US FDA pregnancy category of Cefpodoxime is B. There is, however, no adequate and well-controlled study in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Cefpodoxime have been shown to be excreted in human milk. So, caution should be exercised when Cefpodoxime is administered to a nursing woman.
    Pediatric usageView
    Patients with severe renal impairment (creatinin clearance <30 ml/min) the dosing intervals should be increased to 24 hourly. The dosage adjustment is not require in cases of hepatic impairment.
    ReconstitutionView
    Step 1: Shake the bottle well to loosen the powder.
    Step 2    : Add boiled and cooled water in the bottle.
    Step 3    : Shake until powder is completely mixed with water.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Cefdox

    Cefpodoxime Proxetil
    Tablet 200 mg Allopathic Third generation Cephalosporins

    Indications

    Urinary tract infection

    Indication detailsView
    Cefpodoxime is indicated for the treatment of infections caused by susceptible microorganism, listed below:
    • Acute otitis media caused by Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenza, Moraxella catarrhalis (including beta-lactamase producing strains).
    • Pharyngitis/tonsillitis caused by Streptococcus pyogenes.
    • Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase producing strains), Streptococcus pneumoniae and Moraxella catarrhalis.
    • Community acquired pneumonia caused by S. pneumoniae or H. influenza (including beta-lactamase-producing strains).
    • Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae (non-beta-lactamase-producing strains only), or M. catarrhalis.
    • Skin and skin structure infections caused by Staphylococcus aureus, Streptococcus pyogenes.
    • Uncomplicated urinary tract infections caused by E. coli, Klebsiella pneumoniae, Proteus mirabilis or Staphylococcus saprophyticus.
    • Uncomplicated gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains).
    • Rectal gonococcal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains).
    Therapeutic classView
    Third generation Cephalosporins
    PharmacologyView
    Cefpodoxime is an oral 3rd generation cephalosporin, which has good stability to beta lactamases and activity against Gram negative and Gram positive bacteria. It is indicated for the treatment of infections either before the infecting organism has been identified. It is a prodrug its active metabolite is Cefpodoxime. Approximately 29 to 33% of Cefpodoxime excreted unchanged in the urine in 12 hours.
    DosageView
    Adults and Adolescents (13 years and older)
    • Pharyngitis/tonsillitis: 100 mg 12 hourly, 5 to 10 days
    • Acute maxillary sinusitis: 200 mg 12 hourly, 10 day
    • Community acquired pneumonia: 200 mg 12 hourly, 14 days
    • Acute bacterial exacerbations of chronic bronchitis: 200 mg 12 hourly, 10 days
    • Skin and skin structure: 400 mg 12 hourly, 7 to 14 days
    • Uncomplicated urinary tract infection: 100 mg 12 hourly, 7 days
    • Uncomplicated gonorrhea: single dose of 200 mg
    • Rectal gonococcal infections in women: single dose of 200 mg
    Infants and Pediatric Patients (2 months to 12 years)
    • Acute otitis media: 5 mg/kg body weight 12 hourly, 5 days
    • Pharyngitis /tonsillitis: 5 mg/kg body weight 12 hourly, 5 to 10 days
    • Acute maxillary sinusitis: 5 mg/kg body weight 12 hourly, 10 days
    Side effectsView
    Cefpodoxime has very few side effects. Possible side effects include gastrointestinal disorders (such as- diarrhea, nausea, vomiting and abdominal pain), rash, urticaria and itching.
    ContraindicationsView
    Cefpodoxime is contraindicated in patients with known allergy to cephalosporins.
    PrecautionsView
    In patients with transient or persistent reduction in urinary output due to renal insufficiency, the total daily dose of Cefpodoxime should be reduced. Cefpodoxime should be administered with caution to patients receiving concurrent treatment with potent diuretics. As with other antibiotics, prolonged use of Cefpodoxime may result in overgrowth of non-susceptible organisms.
    InteractionsView
    Cefpodoxime concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H2 blockers reduces peak plasma levels and the extent of absorption respectively. Renal excretion of Cefpodoxime is inhibit by probenecid.
    Pregnancy & lactationView
    US FDA pregnancy category of Cefpodoxime is B. There is, however, no adequate and well-controlled study in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Cefpodoxime have been shown to be excreted in human milk. So, caution should be exercised when Cefpodoxime is administered to a nursing woman.
    Pediatric usageView
    Patients with severe renal impairment (creatinin clearance <30 ml/min) the dosing intervals should be increased to 24 hourly. The dosage adjustment is not require in cases of hepatic impairment.
    ReconstitutionView
    Step 1: Shake the bottle well to loosen the powder.
    Step 2    : Add boiled and cooled water in the bottle.
    Step 3    : Shake until powder is completely mixed with water.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Cefdox DS

    Cefpodoxime Proxetil
    Powder for Suspension 80 mg/5 ml Allopathic Third generation Cephalosporins

    Indications

    Urinary tract infection

    Indication detailsView
    Cefpodoxime is indicated for the treatment of infections caused by susceptible microorganism, listed below:
    • Acute otitis media caused by Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenza, Moraxella catarrhalis (including beta-lactamase producing strains).
    • Pharyngitis/tonsillitis caused by Streptococcus pyogenes.
    • Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase producing strains), Streptococcus pneumoniae and Moraxella catarrhalis.
    • Community acquired pneumonia caused by S. pneumoniae or H. influenza (including beta-lactamase-producing strains).
    • Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae (non-beta-lactamase-producing strains only), or M. catarrhalis.
    • Skin and skin structure infections caused by Staphylococcus aureus, Streptococcus pyogenes.
    • Uncomplicated urinary tract infections caused by E. coli, Klebsiella pneumoniae, Proteus mirabilis or Staphylococcus saprophyticus.
    • Uncomplicated gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains).
    • Rectal gonococcal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains).
    Therapeutic classView
    Third generation Cephalosporins
    PharmacologyView
    Cefpodoxime is an oral 3rd generation cephalosporin, which has good stability to beta lactamases and activity against Gram negative and Gram positive bacteria. It is indicated for the treatment of infections either before the infecting organism has been identified. It is a prodrug its active metabolite is Cefpodoxime. Approximately 29 to 33% of Cefpodoxime excreted unchanged in the urine in 12 hours.
    DosageView
    Adults and Adolescents (13 years and older)
    • Pharyngitis/tonsillitis: 100 mg 12 hourly, 5 to 10 days
    • Acute maxillary sinusitis: 200 mg 12 hourly, 10 day
    • Community acquired pneumonia: 200 mg 12 hourly, 14 days
    • Acute bacterial exacerbations of chronic bronchitis: 200 mg 12 hourly, 10 days
    • Skin and skin structure: 400 mg 12 hourly, 7 to 14 days
    • Uncomplicated urinary tract infection: 100 mg 12 hourly, 7 days
    • Uncomplicated gonorrhea: single dose of 200 mg
    • Rectal gonococcal infections in women: single dose of 200 mg
    Infants and Pediatric Patients (2 months to 12 years)
    • Acute otitis media: 5 mg/kg body weight 12 hourly, 5 days
    • Pharyngitis /tonsillitis: 5 mg/kg body weight 12 hourly, 5 to 10 days
    • Acute maxillary sinusitis: 5 mg/kg body weight 12 hourly, 10 days
    Side effectsView
    Cefpodoxime has very few side effects. Possible side effects include gastrointestinal disorders (such as- diarrhea, nausea, vomiting and abdominal pain), rash, urticaria and itching.
    ContraindicationsView
    Cefpodoxime is contraindicated in patients with known allergy to cephalosporins.
    PrecautionsView
    In patients with transient or persistent reduction in urinary output due to renal insufficiency, the total daily dose of Cefpodoxime should be reduced. Cefpodoxime should be administered with caution to patients receiving concurrent treatment with potent diuretics. As with other antibiotics, prolonged use of Cefpodoxime may result in overgrowth of non-susceptible organisms.
    InteractionsView
    Cefpodoxime concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H2 blockers reduces peak plasma levels and the extent of absorption respectively. Renal excretion of Cefpodoxime is inhibit by probenecid.
    Pregnancy & lactationView
    US FDA pregnancy category of Cefpodoxime is B. There is, however, no adequate and well-controlled study in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Cefpodoxime have been shown to be excreted in human milk. So, caution should be exercised when Cefpodoxime is administered to a nursing woman.
    Pediatric usageView
    Patients with severe renal impairment (creatinin clearance <30 ml/min) the dosing intervals should be increased to 24 hourly. The dosage adjustment is not require in cases of hepatic impairment.
    ReconstitutionView
    Step 1: Shake the bottle well to loosen the powder.
    Step 2    : Add boiled and cooled water in the bottle.
    Step 3    : Shake until powder is completely mixed with water.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Ceferon

    Cefixime Trihydrate
    Powder for Suspension 100 mg/5 ml Allopathic Third generation Cephalosporins

    Indications

    Urethritis

    Indication detailsView
    Cefixime is indicated in the treatment of the following infections when caused by the susceptible strains of the designated microorganisms:
    • Uncomplicated urinary tract infections caused by Escherichia coli and Proteus mirabilis.
    • Otitis Media caused by Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pyogenes.
    • Pharyngitis and tonsillitis caused by Streptococcus pyogenes.
    • Acute bronchitis and acute exacerbations of chronic bronchitis caused by Streptococcus pneumoniae and Haemophilus influenzae.
    • Uncomplicated gonorrhoea (cervical/urethral) caused by Neisseria gonorrhoeae.
    Therapeutic classView
    Third generation Cephalosporins
    PharmacologyView
    Cefixime is a third generation semisynthetic cephalosporin antibiotic for oral administration. It is bactericidal against a broad spectrum of gram positive and gram negative bacteria at easily achievable plasma concentrations. It kills bacteria by interfering in the synthesis of bacterial cell wall. It is highly stable in the presence of Beta-lactamase enzyme. As a result, many organisms resistant to penicillins and some cephalsporins due to the presence of beta-lactamases, may be susceptible to Cefixime. Absorption of it is about 40% to 50% whether administered with or without food.
    DosageView
    The usual course of treatment is 7 days. This may be continued for up to 14 days depending on the severity of the infection.

    Adult and children over 12 years: The recommended adult dose is 200-400 mg (1 to 2 capsules) daily, given either as a single dose or in two divided doses. For the treatment of uncomplicated cervical/urethral gonococcal infections, a single oral dose of Cefixime 400 mg is recommended.

    Children (6 month or older): Usually 8 mg/kg/day given as a single dose or in two divided doses or may be given as following
    • ½-1 year: 75 mg daily.
    • 1-4 years: 100 mg daily.
    • 5-10 years: 200 mg daily.
    • 11-12 years: 300 mg daily
    • In typhoid fever, dosage should be 10 mg/kg/day for 14 days.
    Children (under 6 month): The safety and efficacy of Cefixime has not been established in children aged less than 6 months.
    Side effectsView
    The drug is generally well tolerated. The most frequent side effects are diarrhoea and stool changes; that have been more commonly associated with higher doses. Other side effects are nausea, abdominal pain, dyspepsia, vomiting, flatulence, headache and dizziness. Allergies in the form of rash, pruritus, urticaria, drug fever and arthralgia have been reported. These reactions usually subsided upon dicontinuation of therapy.
    ContraindicationsView
    It is contraindicated in hypersensitivity to Cefixime or other cephalosporins.
    PrecautionsView
    The drug should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis. The drug should be given with caution in patients with marked impaired renal function as well as those undergoing continuous ambulatory peritoneal dialysis and hemodialysis. Dosage adjustment is only necessary in severe renal failure (creatinine clearance < 20 ml/min), in that case a dose of 200 mg once daily should not be exceeded.
    InteractionsView
    Carbamazepine: Concomitant use elevates the carbamazepine level. Warfarin and other anticoagulants: Concomitant use increases prothrombin time.
    Pregnancy & lactationView
    There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. It is not known that Cefixime is excreted in human milk. So, caution should be exercised when Cefixime is administered to a nursing woman.
    Overdose effectsView
    Gastric Lavage may be indicated; otherwise, no specific antidote exists. Cefixime is not removed in significant quantities from the circulation by hemodialysis or peritoneal dialysis. Adverse reactions in small numbers of healthy adult volunteers receiving single doses up to 2 g of Cefixime did not differ from the profile seen in patients treated at the recommended doses.
    StorageView
    Keep below 30ºC temperature, protected from light & moisture. Keep out of the reach of children.

    Ceferon

    Cefixime Trihydrate
    Capsule 200 mg Allopathic Third generation Cephalosporins

    Indications

    Urethritis

    Indication detailsView
    Cefixime is indicated in the treatment of the following infections when caused by the susceptible strains of the designated microorganisms:
    • Uncomplicated urinary tract infections caused by Escherichia coli and Proteus mirabilis.
    • Otitis Media caused by Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pyogenes.
    • Pharyngitis and tonsillitis caused by Streptococcus pyogenes.
    • Acute bronchitis and acute exacerbations of chronic bronchitis caused by Streptococcus pneumoniae and Haemophilus influenzae.
    • Uncomplicated gonorrhoea (cervical/urethral) caused by Neisseria gonorrhoeae.
    Therapeutic classView
    Third generation Cephalosporins
    PharmacologyView
    Cefixime is a third generation semisynthetic cephalosporin antibiotic for oral administration. It is bactericidal against a broad spectrum of gram positive and gram negative bacteria at easily achievable plasma concentrations. It kills bacteria by interfering in the synthesis of bacterial cell wall. It is highly stable in the presence of Beta-lactamase enzyme. As a result, many organisms resistant to penicillins and some cephalsporins due to the presence of beta-lactamases, may be susceptible to Cefixime. Absorption of it is about 40% to 50% whether administered with or without food.
    DosageView
    The usual course of treatment is 7 days. This may be continued for up to 14 days depending on the severity of the infection.

    Adult and children over 12 years: The recommended adult dose is 200-400 mg (1 to 2 capsules) daily, given either as a single dose or in two divided doses. For the treatment of uncomplicated cervical/urethral gonococcal infections, a single oral dose of Cefixime 400 mg is recommended.

    Children (6 month or older): Usually 8 mg/kg/day given as a single dose or in two divided doses or may be given as following
    • ½-1 year: 75 mg daily.
    • 1-4 years: 100 mg daily.
    • 5-10 years: 200 mg daily.
    • 11-12 years: 300 mg daily
    • In typhoid fever, dosage should be 10 mg/kg/day for 14 days.
    Children (under 6 month): The safety and efficacy of Cefixime has not been established in children aged less than 6 months.
    Side effectsView
    The drug is generally well tolerated. The most frequent side effects are diarrhoea and stool changes; that have been more commonly associated with higher doses. Other side effects are nausea, abdominal pain, dyspepsia, vomiting, flatulence, headache and dizziness. Allergies in the form of rash, pruritus, urticaria, drug fever and arthralgia have been reported. These reactions usually subsided upon dicontinuation of therapy.
    ContraindicationsView
    It is contraindicated in hypersensitivity to Cefixime or other cephalosporins.
    PrecautionsView
    The drug should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis. The drug should be given with caution in patients with marked impaired renal function as well as those undergoing continuous ambulatory peritoneal dialysis and hemodialysis. Dosage adjustment is only necessary in severe renal failure (creatinine clearance < 20 ml/min), in that case a dose of 200 mg once daily should not be exceeded.
    InteractionsView
    Carbamazepine: Concomitant use elevates the carbamazepine level. Warfarin and other anticoagulants: Concomitant use increases prothrombin time.
    Pregnancy & lactationView
    There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. It is not known that Cefixime is excreted in human milk. So, caution should be exercised when Cefixime is administered to a nursing woman.
    Overdose effectsView
    Gastric Lavage may be indicated; otherwise, no specific antidote exists. Cefixime is not removed in significant quantities from the circulation by hemodialysis or peritoneal dialysis. Adverse reactions in small numbers of healthy adult volunteers receiving single doses up to 2 g of Cefixime did not differ from the profile seen in patients treated at the recommended doses.
    StorageView
    Keep below 30ºC temperature, protected from light & moisture. Keep out of the reach of children.